Abstracts tagged "Fast Track Clinic"

Abstract Number: 0652 • ACR Convergence 2021
Application of a GCA Probability Score to Patients Referred to a GCA Fast Track Clinic
Mmoloki Mathake¹, Julia Murdoch², Andrew Taylor³, Jean-Louis deSousa², Kathy Jao², Rachel Li² and Helen Keen⁴, ¹Fiona Stanley Hospital, Beckenham, Australia, ²Royal Perth Hospital, Perth, Australia, ³Fiona Stanley Hospital, Murdoch, Australia, ⁴Fiona Stanley Hospital, Perth, Australia
Background/Purpose: Giant cell arteritis (GCA) is the most common large vessel vasculitis, and may be associated with irreversible blindness(1). It is therefore essential to make…
Abstract Number: 1394 • ACR Convergence 2021
Vascular Ultrasound for Giant Cell Arteritis: An Effective Diagnostic Modality for a Fast Track Clinic in the United States
Charlie Oshinsky¹, Alison Bays¹, Ingeborg Sacksen², Elizabeth Jernberg³, Eugene zierler¹, Andreas Diamantopoulos⁴ and Scott Pollock¹, ¹University of Washington, Seattle, WA, ²University of Washington, Bellingham, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴Akerhus University Hospital, Brum, Norway
Background/Purpose: Giant cell arteritis (GCA) is the most common form of large vessel vasculitis. Prompt diagnosis and treatment of GCA is vital to prevent vision…
Abstract Number: 1395 • ACR Convergence 2021
Utility and Validity of the Southend Pretest Probability Score (SPTPS) in a Giant Cell Arteritis Fast Track Clinic: Analysis in a Spanish Cohort of 297 Patients
Elisa Fernández-Fernández¹, Irene Monjo² and Eugenio De Miguel³, ¹Rheumatology department, La Paz University Hospital, Madrid, Spain, ²Hospital La Paz - IdiPAZ, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: The implementation of fast track clinics (FTC) has enabled quick diagnosis and reduced the blindness rate of giant cell arteritis (GCA). Recently, the Southend…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].